Wednesday at 11:30 am: Jeremy Levin sounds the alarm on biotech

Biotech exec Jeremy Levin on the industry's strategic turning point

Biotech veteran Jeremy Levin presents "Biotech in the Balance," a book framing the industry as a strategic asset under threat — and outlining a recovery roadmap amid declining public trust and market pressure. For tech and life-sciences executives, it signals a broader reckoning: biotech's pipeline value depends increasingly on governance, narrative, and policy positioning, not just R&D output.